CT and MRI studies of hepatic angiosarcoma

Zhang, J.-X.; Zhou, Shangcheng; Wang, J.; Huang, Yaoqu; Li, J.; Yu, Xuerong; Wang, R.-N.

doi:10.1016/j.crad.2018.12.013

Cited by 19 publications

(16 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most types of hepatic angiosarcoma share characteristic CT and MRI features of indistinct border, heterogeneous density, and frequent intratumoral hemorrhage; and typical centripetal heterogeneous enhancement on enhanced imaging. In addition, highly malignant angiosarcoma shows no enhancement due to intratumoral hemorrhage, cystic degeneration, and necrosis [48].…”

Section: Hepatic Angiosarcomamentioning

confidence: 99%

“…Single mass and mixed massive mass types of hepatic angiosarcoma generally show high FDG uptake [49,50], which is considered to be related to overexpression of GLUT-1 [48]; and diffuse nodule type sometimes shows a false-negative accumulation of FDG due to lower cellular density, because of intratumoral hemorrhage and necrosis [51].…”

Section: Hepatic Angiosarcomamentioning

confidence: 99%

See 1 more Smart Citation

FDG-PET/CT imaging findings of hepatic tumors and tumor-like lesions based on molecular background

et al. 2020

View full text Add to dashboard Cite

The usefulness of whole-body 18-fluoro-2-deoxyglucose (FDG)-fluorodeoxyglucose positron emission (PET)/computed tomography (CT) is established for assessment of disease staging, detection of early disease recurrence, therapeutic evaluation, and predicting prognosis in various malignancies; and for evaluating the spread of inflammation. However, the role of FDG-PET/CT for the liver is limited because CT and magnetic resonance imaging (MRI) can provide an accurate diagnosis of most tumors. In addition, in other potentially useful roles there are several pitfalls in the interpretation of FDG uptake in PET/CT imaging. Accurate evaluation demands knowledge of the FDG uptake of each lesion, including potential negative and positive uptakes, and requires an understanding of the underlying background of the molecular mechanisms. The degree of FDG uptake is dependent on cellular metabolic rate and the expression of glucose transporter, hexokinase, and glucose-6-phosphatase, which in turn are closely affected by biological characteristics such as pathological category (e.g., adenocarcinoma, squamous cell carcinoma, small cell cancer, transitional cell cancer, neuroendocrine tumor, sarcoma, lymphoma), tumor differentiation, histological behavior (e.g., solid, cystic, mucinous), and intratumoral alterations (e.g., necrosis, degeneration, hemorrhage). Correlation with the CT and MRI findings, which also precisely depict the pathological findings, is important to avoid misdiagnosis.

show abstract

Section: Hepatic Angiosarcomamentioning

confidence: 99%

Section: Hepatic Angiosarcomamentioning

confidence: 99%

FDG-PET/CT imaging findings of hepatic tumors and tumor-like lesions based on molecular background

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Because of the low incidence and lack of specific clinical manifestations and tumor markers of PHA, most patients with PHA are initially misdiagnosed mainly as having hepatocellular carcinoma, metastatic carcinoma of the liver, hepatic hemangioma, or cholangiocarcinoma [9,11,12]. Imaging, including abdominal CT and magnetic resonance imaging, remains essential for an initial diagnosis of PHA.…”

Section: Discussionmentioning

confidence: 99%

“…Imaging, including abdominal CT and magnetic resonance imaging, remains essential for an initial diagnosis of PHA. Various appearances of hepatic angiosarcoma on abdominal CT scans have been described in case reports and case series [11,12]. Few reports on the appearance of hepatic angiosarcoma have revealed predominant hypoattenuation compared with the surrounding hepatic parenchyma in unenhanced CT scans; most lesions are hypoattenuated compared with normal liver tissue, but some lesions can be hyperattenuated after images are contrast enhanced [9].…”

Section: Discussionmentioning

confidence: 99%

Prognosis of Aggressive Treatment of Primary Hepatic Angiosarcoma: A Single-Center Experience

Chen¹,

Chen²,

Chen³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background and Aims: Of all primary liver tumors, primary hepatic angiosarcoma (PHA) is a rare and aggressive malignant vascular tumor. The standard therapeutic care for hepatic angiosarcoma remains unclear. This study compared the survival outcomes of aggressive treatment (resection and liver transplant) and nonaggressive treatment (chemotherapy, transarterial chemoembolization [TACE], and conservative treatments) for patients with PHA and analyzed the prognostic factors influencing survival. Materials and Methods: Data of patients diagnosed as having PHA at our facility were retrospectively reviewed. The primary outcome was survival time. The secondary outcome was calculated baseline characteristics. Results: We included a total of 19 patients, who were divided into 2 treatment groups: aggressive (8 patients had undergone resection or transplants) and nonaggressive (11 patients had undergone TACE, chemotherapy, or conservative treatment). The mean survival time was 233.1 ± 189.7 days in the aggressive treatment group and 146.5 ± 115.8 days in the nonaggressive treatment group. A Kaplan-Meier plot revealed no significant difference in survival time between the 2 treatment groups (P = .3256). Conclusions: The survival time of patients receiving aggressive treatment was longer than that of those receiving nonaggressive treatment. The long term survival time in some selective cases of aggressive treatment will be achieved. Thought a difference was not significant between the groups. Because the number of patients was limited, more cases are required to confirm these findings.

show abstract

“…Microscopically, the mesenchyma of angiosarcoma are composed of epithelial and spindle cells, whereas the parenchyma consists of endothelium-lined vascular channels [ 6 ]. In a study of hepatic angiosarcoma reported by Yi et al [ 17 ], highly differentiated hepatic angiosarcoma exhibited annular enhancement in the arterial phase, no internal enhancement, and continuous centripetal filling during the venous and delay phases; however, for poorly differentiated tumors, the enhancement was not obvious or was heterogeneous for all scan phases. In our study, the differentiation degree analysis of lesions with both unenhanced and enhanced-contrast CT scans was only available in three patients.…”

Section: Discussionmentioning

confidence: 99%

Clinical and Imaging Features of Primary Cardiac Angiosarcoma

et al. 2020

View full text Add to dashboard Cite

This study aims to explore computed tomography (CT) and magnetic resonance imaging (MRI) features of patients diagnosed with primary cardiac angiosarcoma. The study involved the analysis of 12 patients diagnosed with primary cardiac angiosarcoma who underwent non-contrast (8/12) or contrast-enhanced CT (10/12) or MRI (4/12). Imaging appearances, including the tumor location and adjacent infiltration, were analyzed. All 12 lesions were located in the right atrium with a broad base. Adjacent invasion including the tricuspid valve and right ventricle (2/12), inferior or superior vena cava (2/12), pericardium (10/12), and right coronary artery (7/12) was common. On unenhanced CT scans, tumors in two patients were homogeneous in density, whereas the others were inhomogeneous. Ten patients showed heterogeneous enhancement. The enhancement pattern showed no direct correlation with the differentiation degree of the tumor. Four lesions manifested as heterogeneous intensity, with hyperintense hemorrhage foci on both T1- and T2-weighted MRI. Three showed rim enhancement and one showed patchy enhancement. Primary cardiac angiosarcoma often involves the right side of the heart with infiltration of peripheral structures. CT features include typical inhomogeneous density on unenhanced scans and heterogeneous centripetal enhancement on enhanced scans. A cauliflower-like appearance on both T1- and T2-weighted MRI is common. The characteristic enhancement pattern of MRI remains to be determined.

show abstract

CT and MRI studies of hepatic angiosarcoma

Cited by 19 publications

References 15 publications

FDG-PET/CT imaging findings of hepatic tumors and tumor-like lesions based on molecular background

FDG-PET/CT imaging findings of hepatic tumors and tumor-like lesions based on molecular background

Prognosis of Aggressive Treatment of Primary Hepatic Angiosarcoma: A Single-Center Experience

Clinical and Imaging Features of Primary Cardiac Angiosarcoma

Contact Info

Product

Resources

About